NDAVAGINALGEL
Approved
Jul 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
CRINONE (progesterone) by AbbVie is clinical pharmacology progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland. First approved in 1997.
Drug data last refreshed 12h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CRINONE is a vaginal gel formulation of progesterone, a naturally occurring steroid essential for endometrial transformation and pregnancy maintenance. It is indicated for assisted reproductive technology and secondary amenorrhea in women requiring progesterone supplementation. The drug works by transforming a proliferative endometrium into a secretory endometrium and increases endometrial receptivity for embryo implantation.
$0.071MPart D
LOE ApproachingProduct is in late lifecycle phase with minimal Part D utilization (123 claims), signaling a mature, specialty-focused commercial operation with likely lean team structure.
Mechanism of Action
CLINICAL PHARMACOLOGY Progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland. In the presence of adequate estrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone is essential for the development of…
Worked on CRINONE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.